Analyst Blog Highlights Featured Stocks Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy GILD?
Source: NASDAQ.COM
- Oracle's Strong Earnings: Oracle's fiscal Q3 2026 results exceeded expectations with revenues and earnings, driven by an 84% surge in cloud infrastructure revenues, reflecting robust AI workload and multicloud demand, although the negative $13.2 billion free cash flow indicates ongoing investment pressures in data center expansions.
- T-Mobile's Underperformance: T-Mobile's shares have declined 10.1% over the past six months, underperforming the industry average, primarily due to high debt and fierce competition; however, its leading postpaid customer growth and record-low churn rate provide a competitive edge, particularly with its 5G spectrum strategy.
- Gilead's Sales Growth Outlook: Gilead's stock has risen 30.6% in the last six months, bolstered by its leading HIV portfolio, with expectations for approximately 6% growth in HIV sales in 2026, further supported by the approval of a long-acting injectable treatment that is expected to enhance revenue.
- National Research's Rising Contract Value: National Research has seen its Total Recurring Contract Value rise to approximately $152 million over five consecutive quarters, despite revenue declines and competitive pressures, indicating potential for future revenue growth supported by its extensive presence in U.S. healthcare systems.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to fall
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 145.210
Low
105.00
Averages
137.88
High
154.00
Current: 145.210
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analyst Blog Highlights Featured Stocks Update
- Oracle's Strong Earnings: Oracle's fiscal Q3 2026 results exceeded expectations with revenues and earnings, driven by an 84% surge in cloud infrastructure revenues, reflecting robust AI workload and multicloud demand, although the negative $13.2 billion free cash flow indicates ongoing investment pressures in data center expansions.
- T-Mobile's Underperformance: T-Mobile's shares have declined 10.1% over the past six months, underperforming the industry average, primarily due to high debt and fierce competition; however, its leading postpaid customer growth and record-low churn rate provide a competitive edge, particularly with its 5G spectrum strategy.
- Gilead's Sales Growth Outlook: Gilead's stock has risen 30.6% in the last six months, bolstered by its leading HIV portfolio, with expectations for approximately 6% growth in HIV sales in 2026, further supported by the approval of a long-acting injectable treatment that is expected to enhance revenue.
- National Research's Rising Contract Value: National Research has seen its Total Recurring Contract Value rise to approximately $152 million over five consecutive quarters, despite revenue declines and competitive pressures, indicating potential for future revenue growth supported by its extensive presence in U.S. healthcare systems.
See More
Investment Strategies Amid Recession Predictions
- CVS Health's Market Position: With over 9,000 locations across the U.S., CVS Health's diversified healthcare services, including pharmacy, primary care, and health insurance, are expected to maintain stable earnings during a recession, boasting a market cap of $97 billion.
- Dividend Appeal: CVS Health offers a dividend yield of 3.4%, significantly higher than the S&P 500's 1.2%, and has increased its dividend by 56.5% over the past decade, highlighting its attractiveness amid economic uncertainty.
- Gilead Sciences' Product Portfolio: Known for its leading HIV medications, including Biktarvy and Descovy, Gilead Sciences is expected to see continued demand for its key products even during economic downturns, with a market cap of $184 billion.
- Robust Dividend Policy: Gilead Sciences has a forward dividend yield exceeding 2.3% and has increased its payouts by 90.7% over the past decade, making it a solid anchor in a diversified portfolio during tough economic times.
See More
Healthcare Stocks to Invest in During Economic Downturns
- CVS Health's Resilience: With over 9,000 locations across the U.S., CVS Health's diversified healthcare services, including pharmacy, primary care, and health insurance, are expected to maintain stable earnings during economic downturns, despite challenges in cost control within its Medicare Advantage business.
- Attractive Dividend Growth: CVS Health offers a dividend yield of 3.4%, significantly higher than the S&P 500's 1.2%, and has increased its dividend by 56.5% over the past decade, highlighting its appeal amid economic uncertainty.
- Gilead Sciences' Product Portfolio: As a leading biotech firm, Gilead Sciences is renowned for its top HIV medications, and while recent sales growth has been sluggish, its robust pipeline, particularly in oncology, is anticipated to drive future sales growth.
- Strong Dividend Policy: Gilead Sciences boasts a forward dividend yield exceeding 2.3%, with a remarkable 90.7% increase in dividends over the past decade, making it a solid anchor for a diversified portfolio during tough economic times.
See More
Latest Wall Street Rating Updates
- BofA Downgrades Qualcomm: Bank of America has downgraded Qualcomm from neutral to underperform with a price target of $145, citing lukewarm projected sales and EPS growth of only 2% and 1% CAGR from 2025 to 2028, significantly lagging the semiconductor sector's expected 17% growth.
- Deutsche Bank Upgrades Teladoc: Deutsche Bank upgraded Teladoc from hold to buy, highlighting an attractive risk/reward profile due to compelling valuation and a deliverable strategy for its BetterHelp business, indicating a strong potential for future growth.
- TD Cowen Upgrades Rivian: TD Cowen upgraded Rivian from hold to buy, projecting full-scale demand for its R2 model to reach between 212,000 and 335,000 units, suggesting significant upside potential against 2027 consensus estimates.
- Morgan Stanley Reiterates Microsoft Overweight: Morgan Stanley reiterated its overweight rating on Microsoft, emphasizing the readiness of its Office product suite for the upcoming Agentic AI offerings, with general availability expected on May 1, 2026, priced at $99 per user per month.
See More
Gilead Sciences Stock Rises Ahead of Positive Earnings Outlook
- Stock Performance: Gilead Sciences (GILD) closed at $146.63, up 1.88% from the previous session, outperforming the S&P 500's 0.83% gain, indicating strong market confidence in its future performance.
- Earnings Expectations: The company is forecasted to report an EPS of $1.86, reflecting a 2.76% increase from the same quarter last year, with expected revenue of $6.86 billion, a 2.93% rise, showcasing stability in its HIV and hepatitis C drug sectors.
- Analyst Ratings: Currently holding a Zacks Rank of #3 (Hold), Gilead's EPS estimate has increased by 0.59% over the past 30 days, suggesting analysts' favorable outlook on the company's health and profitability, which could positively influence stock prices.
- Valuation Analysis: Gilead's forward P/E ratio stands at 16.62, below the industry average of 19.76, indicating its stock may be undervalued, while a PEG ratio of 1.89 suggests strong future earnings growth potential, likely attracting more investor interest.
See More
Three Blue-Chip Stocks Designed for a Shifting Market
Sector Rotation: Investors are moving funds from overvalued sectors, particularly tech, into undervalued sectors like energy and consumer staples, as they seek stability in a rotating market.
Duke Energy: Duke Energy is highlighted as a strong investment option due to its stable dividend yield of around 3.2% and its focus on diverse energy sources, positioning it well for future growth.
Gilead Sciences: Gilead is recognized for its defensive growth potential in the biotech sector, with strong performance in HIV therapies and upcoming product launches expected to drive revenue growth.
Hershey Company: Hershey's stock has seen significant gains, breaking out of a bearish trend, and analysts forecast strong earnings growth, making it a recommended buy in the consumer staples sector.
See More
Analyst Blog Highlights Featured Stocks Update
- Oracle's Strong Earnings: Oracle's fiscal Q3 2026 results exceeded expectations with revenues and earnings, driven by an 84% surge in cloud infrastructure revenues, reflecting robust AI workload and multicloud demand, although the negative $13.2 billion free cash flow indicates ongoing investment pressures in data center expansions.
- T-Mobile's Underperformance: T-Mobile's shares have declined 10.1% over the past six months, underperforming the industry average, primarily due to high debt and fierce competition; however, its leading postpaid customer growth and record-low churn rate provide a competitive edge, particularly with its 5G spectrum strategy.
- Gilead's Sales Growth Outlook: Gilead's stock has risen 30.6% in the last six months, bolstered by its leading HIV portfolio, with expectations for approximately 6% growth in HIV sales in 2026, further supported by the approval of a long-acting injectable treatment that is expected to enhance revenue.
- National Research's Rising Contract Value: National Research has seen its Total Recurring Contract Value rise to approximately $152 million over five consecutive quarters, despite revenue declines and competitive pressures, indicating potential for future revenue growth supported by its extensive presence in U.S. healthcare systems.
See More
Investment Strategies Amid Recession Predictions
- CVS Health's Market Position: With over 9,000 locations across the U.S., CVS Health's diversified healthcare services, including pharmacy, primary care, and health insurance, are expected to maintain stable earnings during a recession, boasting a market cap of $97 billion.
- Dividend Appeal: CVS Health offers a dividend yield of 3.4%, significantly higher than the S&P 500's 1.2%, and has increased its dividend by 56.5% over the past decade, highlighting its attractiveness amid economic uncertainty.
- Gilead Sciences' Product Portfolio: Known for its leading HIV medications, including Biktarvy and Descovy, Gilead Sciences is expected to see continued demand for its key products even during economic downturns, with a market cap of $184 billion.
- Robust Dividend Policy: Gilead Sciences has a forward dividend yield exceeding 2.3% and has increased its payouts by 90.7% over the past decade, making it a solid anchor in a diversified portfolio during tough economic times.
See More
Healthcare Stocks to Invest in During Economic Downturns
- CVS Health's Resilience: With over 9,000 locations across the U.S., CVS Health's diversified healthcare services, including pharmacy, primary care, and health insurance, are expected to maintain stable earnings during economic downturns, despite challenges in cost control within its Medicare Advantage business.
- Attractive Dividend Growth: CVS Health offers a dividend yield of 3.4%, significantly higher than the S&P 500's 1.2%, and has increased its dividend by 56.5% over the past decade, highlighting its appeal amid economic uncertainty.
- Gilead Sciences' Product Portfolio: As a leading biotech firm, Gilead Sciences is renowned for its top HIV medications, and while recent sales growth has been sluggish, its robust pipeline, particularly in oncology, is anticipated to drive future sales growth.
- Strong Dividend Policy: Gilead Sciences boasts a forward dividend yield exceeding 2.3%, with a remarkable 90.7% increase in dividends over the past decade, making it a solid anchor for a diversified portfolio during tough economic times.
See More
Latest Wall Street Rating Updates
- BofA Downgrades Qualcomm: Bank of America has downgraded Qualcomm from neutral to underperform with a price target of $145, citing lukewarm projected sales and EPS growth of only 2% and 1% CAGR from 2025 to 2028, significantly lagging the semiconductor sector's expected 17% growth.
- Deutsche Bank Upgrades Teladoc: Deutsche Bank upgraded Teladoc from hold to buy, highlighting an attractive risk/reward profile due to compelling valuation and a deliverable strategy for its BetterHelp business, indicating a strong potential for future growth.
- TD Cowen Upgrades Rivian: TD Cowen upgraded Rivian from hold to buy, projecting full-scale demand for its R2 model to reach between 212,000 and 335,000 units, suggesting significant upside potential against 2027 consensus estimates.
- Morgan Stanley Reiterates Microsoft Overweight: Morgan Stanley reiterated its overweight rating on Microsoft, emphasizing the readiness of its Office product suite for the upcoming Agentic AI offerings, with general availability expected on May 1, 2026, priced at $99 per user per month.
See More
Gilead Sciences Stock Rises Ahead of Positive Earnings Outlook
- Stock Performance: Gilead Sciences (GILD) closed at $146.63, up 1.88% from the previous session, outperforming the S&P 500's 0.83% gain, indicating strong market confidence in its future performance.
- Earnings Expectations: The company is forecasted to report an EPS of $1.86, reflecting a 2.76% increase from the same quarter last year, with expected revenue of $6.86 billion, a 2.93% rise, showcasing stability in its HIV and hepatitis C drug sectors.
- Analyst Ratings: Currently holding a Zacks Rank of #3 (Hold), Gilead's EPS estimate has increased by 0.59% over the past 30 days, suggesting analysts' favorable outlook on the company's health and profitability, which could positively influence stock prices.
- Valuation Analysis: Gilead's forward P/E ratio stands at 16.62, below the industry average of 19.76, indicating its stock may be undervalued, while a PEG ratio of 1.89 suggests strong future earnings growth potential, likely attracting more investor interest.
See More
Three Blue-Chip Stocks Designed for a Shifting Market
Sector Rotation: Investors are moving funds from overvalued sectors, particularly tech, into undervalued sectors like energy and consumer staples, as they seek stability in a rotating market.
Duke Energy: Duke Energy is highlighted as a strong investment option due to its stable dividend yield of around 3.2% and its focus on diverse energy sources, positioning it well for future growth.
Gilead Sciences: Gilead is recognized for its defensive growth potential in the biotech sector, with strong performance in HIV therapies and upcoming product launches expected to drive revenue growth.
Hershey Company: Hershey's stock has seen significant gains, breaking out of a bearish trend, and analysts forecast strong earnings growth, making it a recommended buy in the consumer staples sector.
See More
